San Francisco, CANCT04925375Now EnrollingIRB Ready

Common Variable Immunodeficiency Clinical Trial in San Francisco, CA

Access cutting-edge common variable immunodeficiency treatment through this phase 2 clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Children's Hospital Medical Center, Cincinnati

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access common variable immunodeficiency specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related common variable immunodeficiency treatment provided free

Apply for This San Francisco Location

Check if you qualify for this common variable immunodeficiency clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Common Variable Immunodeficiency Study in San Francisco

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Fu

Sponsor: Children's Hospital Medical Center, Cincinnati

Who Can Participate

Inclusion Criteria

Diagnosis of CVID according to the international consensus document (ICON)
Age 4 years or above
Serum IgG at least 2 standard deviations below the age adjusted normal
Decreased serum IgA and/or serum IgM
Abnormal specific antibody response to immunization 5.

Exclusion Criteria

of secondary immunodeficiency
On replacement immunoglobulin for at least 6 months and willing to maintain throughout study
Granulomatous-lymphocytic interstitial lung disease with a lymphocytic component diagnosed by lung biopsy prior to study entry, wedge biopsy preferred.
Persistence or worsening of interstitial lung disease measured on serial CT imaging of the lung at least 6 months apart, with the latest assessment within 3 months of study entry.
Signed written informed consent
Willing to allow storage of biological specimens for future use in medical research.
Female subjects of childbearing potential must agree to an effective form of birth control such as hormone based contraceptive, intrauterine device, condoms/barrier, surgically sterile partner, or abstinence.
Fertile, non-vasectomized males with a female partner of childbearing potential should use condoms throughout the study and for 3 months after the last dose Exclusion Criteria:
History of hypersensitivity to abatacept or any of its components
Has received any lymphocyte depleting agents including anti-CD20 monoclonal antibodies, alemtuzumab, ATG in the preceding 6 months
Has received abatacept, cyclophosphamide, tumor necrosis factor inhibitors, or pulse steroids (defined as \>15mg/kg/day of methylprednisone or corticosteroid equivalent) within the past 3 months
Have started or increased any of the following immune modulating drugs within 3 months of enrolling and 3 months from initial CT chest: azathioprine, cyclosporine, tacrolimus, mercaptopurine, methotrexate, mycophenolate mofetil, or sirolimus
History of HIV infection (positive PCR)
Chronic untreated hepatitis B or C (positive PCR)
Active tuberculosis (TB) by positive QuantiFERON gold. If history of latent TB, then must supply evidence of completing treatment.
Persistent Epstein-Barr Virus (EBV) load ≥ 1,000 units/mL blood checked twice at least 1 month apart
Other uncontrolled infections
Live vaccine given within 6 weeks of the start of the trial
Malignancy or treated for malignancy within the past year
Currently pregnant or breast feeding
Life expectancy less than 1 month
Subjects unwilling to self-administer or have a parent/caregiver self-administer subcutaneous injections at home
Other conditions that the investigators feel contraindicate participation in the study Inclusion criteria for Extended Treatment Plan:
Patients must have completed the abatacept for the treatment of Interstitial Lung Disease in Common Variable Immunodeficiency (ABCVILD) trial
Patients must have demonstrated positive response to abatacept.
Patients must provide informed consent to participate in the Extended Treatment Plan. Exclusion criteria for Extended Treatment Plan: • Patients who experienced SAEs during the original trial, and such SAEs were determined as related to treatment, or patients who in the opinion of the investigator would not benefit from the extended treatment option.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT04925375) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Common Variable Immunodeficiency Treatment Options in San Francisco, CA

If you're searching for common variable immunodeficiency treatment options in San Francisco, CA, this clinical trial (NCT04925375) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced common variable immunodeficiency specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all common variable immunodeficiency clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in San Francisco, CA

See all multiple myeloma clinical trials recruiting in San Francisco — not just this study.

Browse Multiple Myeloma Trials in San Francisco →

Browse More Trials by Condition

Multiple Myeloma TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA